Does Aetna Cover Prolia?

How Aetna Classifies Prolia for Coverage

Aetna processes Prolia (denosumab 60 mg) as a medical benefit rather than a pharmacy benefit because the drug is administered by subcutaneous injection in a physician's office or infusion center. This classification means Prolia falls under medical policy rather than the prescription drug formulary. The distinction matters for your wallet.

Under Aetna's Clinical Policy Bulletin for Denosumab, the insurer considers Prolia medically necessary for postmenopausal women with osteoporosis, men with osteoporosis at high fracture risk, patients receiving aromatase inhibitor therapy for breast cancer, men on androgen deprivation therapy for prostate cancer, and patients with glucocorticoid-induced osteoporosis. These indications align with the FDA-approved labeling for denosumab, which received initial approval in 2010 for postmenopausal osteoporosis [1]. Aetna explicitly lists denosumab as "experimental and investigational" for indications outside the FDA label, such as periarticular bone erosion in rheumatoid arthritis or hypercalcemia not related to malignancy [2].

Because Prolia is billed under medical benefit codes (HCPCS code J0897), your cost share is calculated differently than a pharmacy copay. You pay your plan's coinsurance percentage of the allowed amount after meeting your annual deductible. For a patient on a plan with 20% coinsurance and an allowed amount of $1,500, the out-of-pocket cost per injection would be $300 before any assistance programs.

Prior Authorization Requirements

Nearly all Aetna plans require prior authorization before covering Prolia. Your prescribing physician's office must submit clinical documentation to Aetna's utilization management team before the first injection.

The documentation Aetna typically requests includes a confirmed diagnosis of osteoporosis by dual-energy X-ray absorptiometry (DXA) scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip [3]. Aetna also accepts a history of fragility fracture as qualifying evidence, consistent with the National Osteoporosis Foundation (now Bone Health & Osteoporosis Foundation) guidelines that recommend pharmacologic treatment for patients with hip or vertebral fractures regardless of DXA score [4].

The authorization process takes 5 to 15 business days for standard requests. Urgent requests tied to imminent fracture risk or hospital discharge can be processed in 24 to 72 hours. If Aetna denies the prior authorization, your physician can submit a peer-to-peer review request to discuss the clinical rationale with an Aetna medical director. Denial rates for Prolia prior authorizations are not publicly reported by Aetna, but a 2021 JAMA study found that approximately 18% of prior authorization requests for specialty medications are initially denied across commercial insurers, with 40% to 60% of denials overturned on appeal [5].

Keep a copy of your DXA report. Having it ready speeds up the entire process.

Step Therapy: Bisphosphonates Before Prolia

Aetna's step therapy protocol requires most patients to try and fail (or demonstrate intolerance to) at least one oral bisphosphonate before Prolia is approved. This policy reflects the lower cost of generic bisphosphonates and their established efficacy data.

Alendronate (generic Fosamax) costs $10 to $30 per month, compared to approximately $1,900 per Prolia injection every six months. The Fracture Intervention Trial (FIT) demonstrated that alendronate reduced hip fracture risk by 51% (relative risk 0.49 to 95% CI 0.23 to 0.99) and vertebral fracture risk by 47% over three years in women with existing vertebral fractures [6]. Risedronate showed similar results in the VERT trial, reducing new vertebral fractures by 41% at three years [7].

Aetna considers step therapy satisfied under specific circumstances. Documented gastrointestinal intolerance (esophagitis, esophageal ulceration, or inability to remain upright for 30 minutes) qualifies. So does renal impairment with an estimated GFR below 30 to 35 mL/min, since bisphosphonates are cleared renally and contraindicated in severe kidney disease [8]. Osteonecrosis of the jaw or atypical femoral fracture on a prior bisphosphonate also bypasses the step requirement.

If your physician documents continued bone loss (a statistically significant DXA decline exceeding the least significant change, typically 3% to 5% at the lumbar spine) despite 12 or more months of bisphosphonate adherence, Aetna generally approves transition to Prolia. The FREEDOM trial (N=7,868) showed denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared to placebo [9]. These results support Prolia as a second-line or alternative first-line agent when bisphosphonates are not appropriate.

What You Will Pay Out of Pocket

Your actual cost depends on your specific Aetna plan type, your deductible status, and whether you have met your out-of-pocket maximum for the year. The numbers vary widely.

For Aetna Medicare Advantage plans, Prolia is covered under Medicare Part B as a physician-administered injectable. After the Part B deductible ($257 in 2026), most Aetna Medicare Advantage plans charge 20% coinsurance. With the Medicare allowed amount for denosumab typically between $1,200 and $1,600 depending on geographic region, the patient responsibility ranges from $240 to $320 per injection before any supplemental coverage. Some Aetna Medicare Advantage plans with enhanced benefits reduce this to $0 to $50 per injection.

For Aetna commercial PPO and HMO plans, coinsurance rates of 10% to 30% are standard for specialist office visits and in-office injectables. A patient with 20% coinsurance on a plan allowing $1,500 for the injection and administration would owe $300 per dose. Two doses per year means $600 annually in coinsurance alone, assuming the deductible has been met.

For Aetna high-deductible health plans (HDHPs), the patient bears full cost until the deductible (commonly $1,600 to $3,200 for individual coverage in 2026) is satisfied. A patient receiving their first Prolia injection in January before any other medical expenses would pay the full allowed amount out of pocket.

Amgen's Prolia Patient Assistance Program offers a copay card for commercially insured patients that can reduce out-of-pocket costs to as little as $0 per injection, with a maximum annual benefit typically around $3,000 to $6,000. Medicare and Medicaid beneficiaries are not eligible for commercial copay cards under the federal Anti-Kickback Statute, but may qualify for Amgen's separate patient assistance foundation programs based on income.

Aetna Medicare Advantage vs. Aetna Commercial: Key Differences

The coverage pathway for Prolia differs between Aetna's Medicare Advantage products and its commercial group or individual plans. Understanding which plan type you have determines how to approach the authorization process.

Under Medicare Part B, injectable osteoporosis drugs are covered for women meeting specific criteria established by the Bone Mass Measurement Act of 1997: estrogen-deficient women at clinical risk for osteoporosis, individuals with vertebral abnormalities on imaging, patients receiving or planning glucocorticoid therapy, patients with primary hyperparathyroidism, and those being monitored to assess response to FDA-approved osteoporosis therapy [10]. Aetna Medicare Advantage plans must cover at minimum what Original Medicare covers, so Prolia authorization criteria cannot be more restrictive than CMS national coverage determinations.

Commercial Aetna plans have more latitude. Step therapy requirements, preferred provider restrictions, and quantity limits are set by the employer group's benefit design. A large employer might negotiate a plan with no step therapy for specialty injectables, while a small group plan might impose strict step edits. Check your Summary of Benefits and Coverage (SBC) document or call the number on your Aetna member ID card to confirm your specific plan's requirements.

One consistent rule across both plan types: Prolia must be administered by a healthcare provider. It is not dispensed as a self-administered home injection under Aetna's standard policies, which keeps it classified as a medical benefit rather than a pharmacy benefit [11].

How to Appeal an Aetna Denial for Prolia

An initial denial does not mean permanent denial. Aetna's appeals process follows a structured timeline, and clinically supported appeals have a reasonable success rate.

Within 180 days of receiving a denial letter, you or your physician can file a first-level appeal. The appeal should include the original prior authorization documentation plus any additional clinical evidence. A letter of medical necessity from your treating physician is the most effective supporting document. This letter should reference your specific DXA scores, fracture history, bisphosphonate trial history (drug name, dose, duration, and reason for discontinuation), and relevant comorbidities such as chronic kidney disease that preclude bisphosphonate use [12].

Citing guideline recommendations strengthens the appeal. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend denosumab as a first-line option for patients at very high fracture risk, defined as a recent fracture within 12 months, fractures while on approved therapy, multiple fractures, or a T-score below -3.0 [13]. The Endocrine Society's 2019 guidelines similarly position denosumab as an appropriate initial therapy for postmenopausal women who cannot take oral bisphosphonates [14].

If the first-level appeal is denied, Aetna offers a second-level appeal reviewed by a physician who was not involved in the original decision. After exhausting internal appeals, members can request an external review by an independent review organization (IRO), which is binding on Aetna under the Affordable Care Act's external review provisions. For Medicare Advantage members, the appeals pathway follows CMS regulations: redetermination, reconsideration by a Qualified Independent Contractor, then Administrative Law Judge hearing for amounts exceeding $180 [15].

Why Continuous Coverage Matters with Prolia

Prolia is unique among osteoporosis medications because abrupt discontinuation carries a documented risk of rebound vertebral fractures. This pharmacologic reality makes uninterrupted insurance coverage for Prolia especially important.

The FDA added a warning about this risk in 2022 based on postmarketing data showing that patients who discontinued denosumab experienced rapid bone mineral density loss and, in some cases, multiple vertebral compression fractures within 7 to 12 months of the last injection [16]. A systematic review published in the Journal of Bone and Mineral Research found that the vertebral fracture incidence after denosumab discontinuation was 7.1%, significantly higher than the 4.2% rate observed in patients who had never received the drug [17].

The Endocrine Society recommends that patients transitioning off Prolia should receive a bisphosphonate (preferably zoledronic acid or alendronate) to prevent rebound bone loss [14]. If you anticipate a gap in Aetna coverage due to job change, plan switching, or retirement, work with your physician at least two to three months before your last covered injection to develop a transition plan.

For patients switching from an Aetna commercial plan to Aetna Medicare Advantage (or vice versa) at open enrollment, there should be no gap in Prolia coverage as long as the new plan's prior authorization is submitted before the old plan terminates. Ask your physician's office to initiate the new prior authorization 60 days before the plan transition date.

Other Aetna-Covered Osteoporosis Treatments

If Prolia is denied or you prefer alternatives, Aetna covers several other osteoporosis medications with varying prior authorization requirements and cost-sharing structures.

Generic oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly or 150 mg monthly) are covered as Tier 1 pharmacy benefits on most Aetna formularies with copays of $5 to $30 per month. Ibandronate (Boniva) 150 mg monthly oral is usually Tier 2, with copays of $25 to $60 [18].

Zoledronic acid (Reclast) 5 mg IV annually is covered as a medical benefit. A single infusion per year reduces vertebral fractures by 70% and hip fractures by 41% over three years based on the HORIZON trial (N=7,765) [19]. Prior authorization requirements are similar to Prolia.

Teriparatide (Forteo) and abaloparatide (Tymlos), both parathyroid hormone analogs administered as daily subcutaneous injections, are covered under Aetna's specialty pharmacy benefit for severe osteoporosis. These anabolic agents typically require prior authorization documenting very high fracture risk or failure of antiresorptive therapy. The annual cost exceeds $25,000, and Aetna usually limits treatment to 24 months per the FDA-labeled duration [20].

Romosozumab (Evenity) 210 mg monthly for 12 months is the newest anabolic option. The ARCH trial showed romosozumab followed by alendronate reduced new vertebral fractures by 48% compared to alendronate alone at 24 months [21]. Aetna covers Evenity with prior authorization for postmenopausal women at very high fracture risk, but the cardiovascular safety signal identified in the ARCH trial (higher rates of serious cardiovascular events with romosozumab) triggers additional documentation requirements. Patients with a history of myocardial infarction or stroke within the preceding year are generally excluded from coverage.

Tips for Getting Prolia Covered by Aetna

A few practical steps can accelerate your coverage approval and reduce your costs.

Get your DXA scan at an Aetna in-network facility. Out-of-network DXA results are still clinically valid for authorization purposes, but an in-network scan avoids a separate out-of-network cost. Receive Prolia injections at your physician's office rather than a hospital outpatient department. Hospital-based administration carries higher facility fees, which increase your coinsurance obligation.

Ask your physician to use the specific diagnosis codes that match Aetna's medical policy criteria. For postmenopausal osteoporosis, ICD-10 code M81.0 (age-related osteoporosis without current pathological fracture) or M80.08XA (age-related osteoporosis with current pathological fracture) should appear on the prior authorization and the claim. Mismatched diagnosis codes are a common reason for initial denials that are easily corrected.

Enroll in Amgen's copay assistance before your first injection if you are commercially insured. The application process takes 5 to 10 minutes and can be completed at your physician's office or online. For Medicare beneficiaries, ask Amgen about their safety net foundation or contact the Bone Health & Osteoporosis Foundation for additional financial assistance resources.

Keep records of every injection date, prior authorization approval letter, and explanation of benefits (EOB) statement. Because Prolia must not be abruptly stopped, having a documented treatment history simplifies any future authorization or appeal process with Aetna or a subsequent insurer. Your next injection should be scheduled within 7 months of the prior dose to maintain the dosing interval and avoid rebound fracture risk [22].